STCube

STCube Accounts Payable

The Accounts Payable of STCube (052020.KQ) as of Oct 24, 2026 is 20.26 M KRW. In the previous year, Accounts Payable was 601.42 M KRW — a change of -96.63% (lower).

Accounts Payable

20.26 MKRW

YoY

-96.63%

Last updated:

Accounts Payable of STCube is 2025 20.26 M KRW. Accounts Payable of STCube was 2024 601.42 M KRW. It decreases by -96.63% lower compared to the previous year.

The STCube Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2018
307.69 M KRW
Jan 1, 2019
358.89 M KRW
Jan 1, 2020
635.24 M KRW
Jan 1, 2021
402.47 M KRW
Jan 1, 2022
50.02 M KRW
Jan 1, 2023
564.71 M KRW
Jan 1, 2024
601.42 M KRW
Jan 1, 2025
20.26 M KRW
The STCube Accounts Payable history
YEARAccounts PayableYoY
20.26 MKRW-96.63%
601.42 MKRW+6.50%
564.71 MKRW+1,029.02%
50.02 MKRW-87.57%
402.47 MKRW-36.64%
635.24 MKRW+77.00%
358.89 MKRW+16.64%
307.69 MKRW-66.71%
924.33 MKRW+2.33%
903.29 MKRW+93.78%
466.14 MKRW+62.04%
287.66 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

Accounts Payable of STCube is 20.26 M KRW in 2025.

Accounts Payable of STCube changed from 601.42 M KRW to 20.26 M KRW, representing a -96.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable STCube since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's STCube historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — STCube

All Key Metrics — STCube